52600-52-9

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 5-cyano-1,6-dihydro-2-methyl-6-oxo-3-pyridinecarboxylate is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structure of various drugs.
Used in Agrochemical Industry:
Ethyl 5-cyano-1,6-dihydro-2-methyl-6-oxo-3-pyridinecarboxylate is used as an intermediate in the synthesis of agrochemicals for its potential to be part of the formulation of pesticides or other agricultural products.
Used in Organic Compounds Production:
Ethyl 5-cyano-1,6-dihydro-2-methyl-6-oxo-3-pyridinecarboxylate is used as a building block in the production of various organic compounds, contributing to the development of new chemical entities for different applications.

InChI:InChI=1/C10H10N2O3/c1-3-15-10(14)8-4-7(5-11)9(13)12-6(8)2/h4H,3H2,1-2H3,(H,12,13)

Upstream product

• 105-56-6 ethyl 2-cyanoacetate 
• 3788-94-1 2-ethoxymethylene-3-oxobutanoic acid ethyl ester 
• 2620-30-6 sodium acetylamide 
• 7664-41-7 ammonia 
• 107-91-5 cyanoacetic acid amide 
• 134653-70-6 ethyl 2-[(dimethylamino)methylene]-3-oxobutanoate 
• 109-77-3 malononitrile 
• 141-97-9 ethyl acetoacetate 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 141-52-6 sodium ethanolate 
• 1188-33-6 N,N-dimethylformamide diethyl diacetal 

Downstream Products

• 64119-42-2 ethyl 6-chloro-5-cyano-2-methylnicotinate 
• 139549-30-7 ethyl 6-(benzyloxy)-5-cyano-2-methylnicotinate 
• 147440-60-6 2-(benzyloxy)-5-(hydroxymethyl)-6-methylnicotinaldehyde 
• 139549-33-0 2-(benzyloxy)-5-(aminocarbonyl)-6-methylnicotinaldehyde 
• 139549-31-8 2-(benzyloxy)-5-(aninocarbonyl)-6-methylnicotinonitrile 
• 139549-35-2 2-(benzyloxy)-3-<2-(benzoxazol-2-yl)ethenyl>-5-cyano-6-methylpyridine 
• 147440-52-6 trans-2-(benzyloxy)-3-<2-(benzoxazol-2-yl)ethenyl>-5-(methoxymethyl)-6-methylpyridine 
• 139549-34-1 2-(benzyloxy)-3-<2-(benzoxazol-2-yl)ethenyl>-6-methylpyridine-5-carboxamide 
• 103038-00-2 ethyl 5-cyano-2-methylnicotinate 
• 485-35-8 1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one 
• 919351-41-0 ethyl 6-{4-[(benzylsulfonyl)carbamoyl]-piperidin-1-yl}-5-cyano-2-methylpyridine-3-carboxylate 
• 898228-08-5 ethyl 5-cyano-6-(1,4-diazepan-1-yl)-2-methylnicotinate 
• 4241-27-4 1,2-dihydro-6-methyl-2-oxo-3-pyridinecarbonitrile 

Relevant academic research and scientific papers

Development of an efficient and practical route for the multikilogram manufacture of ethyl 5-cyano-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate and ethyl 6-chloro-5-cyano-2-methylnicotinate, key intermediates in the preparation of P2Y12 antagonists

Elucidation of the mechanism of formation of two major impurities in the synthetic route towards key intermediate ethyl 5-cyano-2-methyl-6-oxo-1,6- dihydropyridine-3-carboxylate 1, led directly to the development of a route with significant process improvements in terms of yield, purity, and operability. The overall process yield increased from 15% to 73% without the need for extra purification steps, giving the key intermediate ethyl 6-chloro-5-cyano-2- methylnicotinate, 2, in excess of 80 kg to support clinical development.

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

HETEROCYCLIC COMPOUND

A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent for the prophylaxis or treatment of diabetes mellitus are provided.

Development of a Multi-Kilogram-Scale Synthesis of AZD1283: A Selective and Reversible Antagonist of the P2Y12 Receptor

Ethyl 6-chloro-5-cyano-2-methylnicotinate (4) was coupled with 4-piperidinecarboxylic acid (isonipecotic acid) in 81% yield to pyridine acid 10. An amide coupling between 10 and benzylsulfonamide (6) afforded AZD1283 (1) in 79% yield using CDI as coupling reagent. The synthesis has been developed and scaled up to 20 kg batches of 1, supporting preclinical and clinical studies. Development work towards 2-chloropyridine 4 and benzylsulfonamide (6) is included.

Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives

1,8-Naphthyridine derivatives related to 17 (ITH4012), a neuroprotective compound reported by our research group, have been synthesized. In general, they have shown better inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) than mo

2-AMINO-6-ALKYL SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS P2Y12 INHIBITORS 308

The present invention relates to certain new pyridin analogues of Formula ( I ) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular disease

New Pyridine Analogues IV

The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases

NEW PYRIDINE ANALOGUES

The present invention relates to certain new pyridin analogues of Formula ( I ) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular disease

NEW PYRIDINE ANALOGUES

The present invention relates to certain new pyridin analogues of Formula ( I ) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular disease

New Pyridine Analogues VII 543

The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases